Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10280988 | 0.92 | POLB (0.49) | POLBDDR1GRIN1GRIN2BS1PR1 | |
| SCHEMBL15412561 | 0.89 | POLB (0.40) | POLBDDR1GRIN1GRIN2BS1PR1 | |
| SCHEMBL15426431 | 0.89 | POLB (0.40) | POLBDDR1S1PR1AGPAT2PDE10A | |
| SCHEMBL10280791 | 0.88 | POLB (0.39) | POLBDDR1AGPAT2 | |
| SCHEMBL15426382 | 0.85 | CYP11B1 (0.34) | POLBDDR1GRIN1GRIN2BTP53 | |
| SCHEMBL16746511 | 0.84 | POLB (0.36) | POLBDDR1PDE10ACYP1A2 | |
| SCHEMBL15426388 | 0.84 | TNKS (0.37) | DDR1GAAMAPTPDE10ACYP1A2 | |
| SCHEMBL10281056 | 0.84 | POLB (0.48) | POLBDDR1GRIN1GRIN2BAGPAT2 | |
| SCHEMBL10280699 | 0.84 | POLB (0.48) | POLBDDR1GAAMAPTAGPAT2 | |
| SCHEMBL16803708 | 0.83 | POLB (0.38) | POLBAKT1AKT2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278983-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150148308-A1 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-28 | — | — | US | disclosed |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8853238-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | NR4A1, NR2C2, NR0B1 | POLB 4715/4885DDR1 3079/4885GRIN1 703/4885 |
| US-20150148308-A1 | PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS | SFXN1, OSR1, PIR | POLB 4471/4885DDR1 2720/4885GRIN1 2794/4885 |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | NR4A1, NR2C2, NR0B1 | POLB 4737/4885DDR1 3074/4885GRIN1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.